Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3616 plus anlotinib or standard chemotherapy in advanced lung cancer
CTR20210952Phase 2Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of culmerciclib in small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Apr 2021; status: terminated.
02
Drugs
culmerciclib
03
Conditions
small cell lung cancer (SCLC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20210952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210952.